Immunomic Therapeutics
1 known investors
Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
BiotechMedical Devices
Investors · 1
In the news
- Immunomic Therapeutics - 2026 Company Profile, Funding & Competitors - Tracxntracxn.com · 2021
- HLB helps insert more funding into Immunomic - Global Venturingglobalventuring.com · 2020
- Articles - Immunomic Therapeuticsimmunomix.com · 2017
- Immunomic Therapeutics Closes $3 Million Debt Pre-Series B Round - BioSpacebiospace.com · 2013
- Immunomic Therapeutics 4/25/2014 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com